0001610717-24-000236.txt : 20240509 0001610717-24-000236.hdr.sgml : 20240509 20240509160351 ACCESSION NUMBER: 0001610717-24-000236 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240506 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Felsch Robert Ora CENTRAL INDEX KEY: 0001917819 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36485 FILM NUMBER: 24930357 MAIL ADDRESS: STREET 1: C/O ARDELYX, INC. STREET 2: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARDELYX, INC. CENTRAL INDEX KEY: 0001437402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 510-745-7047 MAIL ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: NTERYX INC DATE OF NAME CHANGE: 20080611 4 1 form4.xml X0508 4 2024-05-06 0001437402 ARDELYX, INC. ARDX 0001917819 Felsch Robert Ora C/O ARDELYX, INC. 400 FIFTH AVENUE, SUITE 210 WALTHAM MA 02451 true See Remarks false Common Stock 2024-05-06 4 M 0 79101 0.84 A 263935 D Common Stock 2024-05-06 4 M 0 40000 2.75 A 303935 D Common Stock 2024-05-06 4 S 0 152988 8.8079 D 150947 D Common Stock 2024-05-06 4 S 0 55000 8.8 D 95947 D Stock Option (Right to Buy) 0.84 2024-05-06 4 M 0 79101 0 D 2032-02-01 Common Stock 79101 61525 D Stock Option (Right to Buy) 2.75 2024-05-06 4 M 0 40000 0 D 2033-01-05 Common Stock 40000 80000 D This transaction was executed in multiple trades in prices ranging from $8.63 to $9.01, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Twenty Five Percent (25%) of the shares subject to the option vest on February 1, 2023 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. SVP Finance and Chief Accounting Officer /s/ Elizabeth Grammer, Attorney-in-Fact for Robert Ora Felsch 2024-05-09